- Home
- ZEPP vs NRXS Comparison
ZEPP vs NRXS Comparison
Compare ZEPP & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ZEPP | NRXS |
|---|---|---|
| Founded | 2013 | 2011 |
| Country | Netherlands | United States |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.9M | 78.9M |
| IPO Year | 2017 | 2023 |
Fundamental Metrics
Financial Performance| Metric | ZEPP | NRXS |
|---|---|---|
| Price | $5.50 | $6.25 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | 35.4K | ★ 93.0K |
| Earning Date | 05-18-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 22.13 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $3,569,282.00 |
| Revenue This Year | $778.34 | $172.91 |
| Revenue Next Year | N/A | $115.71 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 32.89 |
| 52 Week Low | $3.85 | $2.21 |
| 52 Week High | $61.50 | $9.33 |
Technical Indicators
Market Signals| Indicator | ZEPP | NRXS |
|---|---|---|
| Relative Strength Index (RSI) | 58.81 | 41.86 |
| Support Level | $4.04 | $5.77 |
| Resistance Level | $5.63 | $7.62 |
| Average True Range (ATR) | 0.37 | 0.49 |
| MACD | 0.16 | -0.03 |
| Stochastic Oscillator | 85.80 | 47.37 |
Price Performance
Historical ComparisonAbout ZEPP Zepp Health Corporation
Zepp Health Corp is engaged in the business of manufacturing smart health wearable products. The company operates in one segment which is Amazfit-branded products. The product portfolio includes smartwatches and fitness bands. Geographically, the group generates revenue from Asia-Pacific, Europe, North America and others.
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).